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Results

Abstract
Ureteral cancer is extremely rare, with only 3530 cases
predicted in 2016. Therefore, published studies on ureteral
cancers are limited to single-institution retrospective
studies, which have not elucidated a clear recommendation
on the best treatment modality. Large cancer databases
such as the Surveillance, Epidemiology, and End Results
program (SEER) are ideal for providing data for these rare
cancers. Epidemiological studies using the SEER database
with large sample sizes (13,800) found rising incidence of
ureteral cancer over the past 30 years with worsened
outcomes in older patients, males, and patients with
regional/distant spread. However, to date, these studies
have not used the available data in the SEER databases to
stratify survival outcomes based on different treatment
modalities. The purpose of this study is to assess the
overall survival (OSS), cause-specific survival (CSS) and
effect of intervention (surgery and postoperative
radiotherapy) in patients with ureteral carcinoma.

Methods
The Surveillance, Epidemiology, and End Results (SEER)
database is a national cancer database run by the National
Cancer Institute that records all incident cases from 18
registries covering 28% of the US population. The SEER
registries collect data on patient demographics, primary
tumor site, disease extent, course of treatment and follow
up. Data is de-identified and available for public use. Using
the SEER database, we identified patients with
pathologically confirmed primary tumor of renal pelvis and
ureters using International Classification of Diseases codes
ICD-O-3 codes 65.9 (renal pelvis) and 66.9 (ureter) who
underwent attempted curative surgery for their diagnosis
between 1995 and 2012. Exclusion criteria included in-situ
disease, metastatic disease, preoperative radiotherapy,
brachytherapy, or patients with incomplete information
regarding tumor staging, treatment or outcomes. Localized
disease was defined as “confined to the organ of origin
without extension beyond the primary organ” while a tumor
with regional extension were those with “direct extension to
adjacent organs or structures or spread to regional lymph
nodes” As a result of this inclusion criteria, a total of 6,057
patients were included for analysis. Categorical variables
included histology, patient age at diagnosis, gender, race,
year of diagnosis, primary site (renal pelvis vs. ureter),
extent of disease (localized vs. regional), and use of
adjuvant RT. Cause specific survival (CSS) was the primary
endpoint. This was determined using specified cause of
death from either ureteral or renal pelvis carcinoma and
was measured from date of diagnosis until death. Overall
survival (OS) was measured from the date of diagnosis to
the date of death from any cause. Kaplan-Meier plot and
Wilcoxon test were used to evaluate survival of patients in
regards to radiation. In the next step, patients then stratified
based on the stage to evaluate effects of adjuvant
radiotherapy in each stage.

Overall Survival

6057 patients were identified with a mean age of
70.57±10.37SD, 64.88% were male, 61.32% had renal pelvic
carcinoma and 38.68% had ureteral carcinoma, 2601 (42.94%)
had localized tumor and 3456 (57.06%) had regional disease.
The majority of cases were transitional cell carcinoma (96.67%),
all patients underwent surgery and 217 (3.58%) received
adjuvant RT. For the 5840 patients who only received curative
surgery, 64.81% were male, 61.83% had renal pelvic carcinoma
and 38.17% had ureteral carcinoma, 3611 (61.83%) had
localized tumor and 2229 (38.17%) had regional disease. For the
217 patients who received adjuvant radiotherapy in addition to
curative surgery 66.82% were male, 47.46% had renal pelvic
carcinoma and 52.53% had ureteral carcinoma, 22 (10.14%) had
localized tumor and 195 (89.86%) had regional disease. (table 1)
CSS at 1, 2 and 5 years was 98%, 94.6% and 86.1% without
adjuvant RT and 92.1%, 84.7% and 69.4% with adjuvant RT
(p<0.0001) (figure1).
Given the large variation in disease stage between the subgroup
of patients who received adjuvant RT and those who did not , we
also analyzed survival stratified by disease stage. CSS for local
disease at 1, 2 and 5 years was 98.8%, 97.5% and 91.5%
without adjuvant RT and 90.7%, 85.3% and 85.3% with adjuvant
RT. CSS for regional disease at 1, 2 and 5 years was 97.3%,
92% and 80.7% without adjuvant RT and 92.3%, 84.5% and
66.9% with adjuvant RT. (figures 2 and 3)

Total patients
n=6057

Curative
surgery
n=5840
(96.42%)

Curative surgery +
adjuvant
radiotherapy
n=217 (3.58%)

Sex
Male
Female

3930 (64.88%)
2127 (35.12%)

3785 (64.81%)
2055 (35.19%)

145 (66.82%)
72 (33.18%)

Race
Caucasian
African-American
Others
Unknown

5508 (90.94%)
209 (3.45%)
337 (5.56%)
3 (0.05%)

5313 (90.98%)
201 (3.44%)
323 (5.53%)
3 (0.05%)

195 (89.86%)
8 (3.69%)
14 (6.45%)
0 (0%)

Primary tumor site
Renal pelvis
Ureter

3714 (61.32%)
2343 (38.68%)

3611 (61.83%)
2229 (38.17%)

103 (47.46%)
114 (52.53%)

Tumor stage
Local
Regional

2601 (42.94$%)
3456 (57.06%)

3611 (61.83%)
2229 (38.17%)

22 (10.14%)
195 (89.86%)

5855 (96.67%)
89 (1.47%)
31 (0.51%)

5651 (96.76%)
82 (1.4%)
28 (0.48%)

204 (94.01%)
7 (3.23%)
3 (1.38%)

61 (1.01%)
21 (0.35%)

58 (0.99%)
21 (0.36%)

3 (1.38%)
0 (0%)

Histology
Transitional cell carcinoma
Squamous cell neoplasms
Epithelial neoplasms, not
otherwise specified
Adenocarcinoma
Others

Table 1: Predictors of surgical and adjuvant radiotherapy usage in ureteral
cancer

95% Hazard Ratio
Confidence Limits

Hazard
Ratio

95% Hazard Ratio
Confidence Limits

Radiation:
Yes

1.433

1.233

1.665

2.159

1.634

2.852

Gender:
Female

0.877

0.823

0.935

1.200

1.044

1.378

Stage:
Regional

1.529

1.436

1.627

2.020

1.746

2.338

Primary
site:
Renal
Pelvis

0.977

0.918

1.040

1.202

1.041

1.388

Table 2: Multivariate analysis comparison of overall and cause-specific survival
by prognostic factor

Conclusion
Figure 1: Kaplan-Meier plot of cause-specific survival stratified for all patients by
adjuvant radiotherapy use. Blue line represents patients who only underwent
surgery, red line represents patients who underwent surgery and radiotherapy

On multivariate analysis, older age, regional extension, and
postoperative RT had a negative impact on both overall survival
and cause-specific survival. Specifically, receiving postoperative
RT had a hazard ratio of 2.16 with Confidence Interval of 1.63 to
2.85. Female sex was associated positively with OS but
negatively with CSS. (table 2)
n (%)
Mean ± SD

Hazard
Ratio

Cause-Specific Survival

This is a large population-based study to look at the role of
adjuvant RT in patients with ureteral carcinoma. In this
nonrandomized population, adjuvant RT was used in a
minority of patients and showed a detriment in both OS and
CSS. After stratifying based on stage, adjuvant RT was still
associated with decreased OS and CSS in both localized and
regional disease. However, it is likely that post-op RT was
used in cases where there were pathologic risk features
showing high risks for recurrence, such as R1/R2 resections,
larger tumors, lymph node positive disease, etc. Further
elucidation of risk features and the role of RT in this rare
disease warrant more investigation.
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